the invention may be manufactured as an oral syrup , scored tablet , unscored tablet , or as a capsule . in the most preferred embodiments of the subject invention , the invention is a capsule or a tablet for oral ingestion . formulations and manufacturing techniques for tablets and capsules are well known in the art , and are described , for example , in remington &# 39 ; s pharmaceutical sciences 20th edition , mack publishing company , easton , pa . ( 2000 ), which is incorporated herein by reference . other embodiments of the subject invention may include all of the known modes of administering pharmaceuticals , such as transdermal , buccal , rectal , intravenous , intramuscular , and the like . in general , lower doses of lisinopril are preferred to be co - formulated with lower doses of chlorthalidone , and higher doses of lisinopril tend to be more useful with higher doses of chlorthalidone . more preferred daily doses for adults range from 2 . 5 mg to 100 mg of chlorthalidone and 2 . 5 mg to 100 mg of lisinopril . most preferred daily dose for adults range from 5 mg to 50 mg of chlorthalidone and 5 mg to 50 mg of lisinopril . a preferred example of the dosage of the lisinopril and chlorthalidone formulation is : an even more preferred example of the dosage of the lisinopril and chlorthalidone formulation is : in a preferred embodiment of the novel tablet , lisinopril and chlorthalidone are formulated separately with suitable excipients . a suitable inactive segment is formulated , and the tablet is prepared on a tri - layer tablet press , such as a commercially available multi - layer tablet press manufactured by korsch ag of germany . alternatively , lisinopril and chlorthalidone are co - formulated with suitable excipients and compressed in an appropriate layer press with at least one other layer derived from an inactive composition , e . g ., granulation . in the standard tablets and capsules well known in the art , a suitable co - formulation is prepared and either tableted or encapsulated , and no separately formulated inactive granulation is utilized . for encapsulation , the individually granulated lisinopril and chlorthalidone granules may either be filled in a single capsule or in a double capsule ( capsule inside a capsule ; inner capsule containing one drug and the outer capsule the other ). as is seen in the following example and experimental section , the amount of chlorthalidone and lisinopril can be easily varied as can the amounts of the excipients with the only limitation being the need to form an acceptable tablet . preparation of a tri - layer 10 mg chlorthalidone and 5 mg lisinopril tablet the following ingredients are used at the specified weight percentages to formulate a chlorthalidone active blend composition ; 1 . chlorthalidone and an equal mass of microcrystalline cellulose ( mcc ) are added into a high shear mixer and mixed for 3 minutes . 2 . the mixture from step - 1 is placed in a suitably sized “ v ” blender ; the remaining microcrystalline cellulose and sodium starch glycolate are then added and mixed for 15 minutes . 3 . half of the magnesium stearate is added to the above mixture and blended for 3 minutes . 4 . the blended mixture from step - 3 is dry granulated on a suitable roller compactor . the roller - compacted material is then milled to a particle size suitable for tablet compression . 5 . the milled material from step - 4 is placed in a suitably sized “ v ” blender . the remaining magnesium stearate is added to the blender and the material is mixed for 3 minutes to obtain the final active blend . the following ingredients are used at the specified weight percentages to formulate an inactive blend composition : 1 . the dibasic calcium phosphate , anhydrous , microcrystalline cellulose , and sodium starch glycolate are added to a suitable “ v ” blender and mixed for 15 minutes . 2 . half of the magnesium stearate is added to the above mixture and blended for 3 minutes . 3 . the blended mixture from step - 2 is dry granulated on a suitable roller compactor . the roller - compacted material is milled to a particle size suitable for tablet compression . 4 . the milled material is added to a suitably sized “ v ” blender . the remaining magnesium stearate is added to the blender and the material is mixed for 3 minutes to obtain the final inactive blend . the following ingredients are used at the specified weight percentages to formulate a lisinopril active blend composition ; 1 lisinopril and an equal mass of microcrystalline cellulose ( mcc ) are added into a high shear mixer and mixed for 3 minutes . 2 the mixture from step - 1 is placed in a suitably sized “ v ” blender ; the remaining microcrystalline cellulose and sodium starch glycolate are then added and mixed for 15 minutes . 3 half of the magnesium stearate is added to the above mixture and blended for 3 minutes . 4 the blended mixture from step - 3 is dry granulated on a suitable roller compactor . the roller - compacted material is then milled to a particle size suitable for tablet compression . 5 the milled material from step - 4 is placed in a suitably sized “ v ” blender . the remaining magnesium stearate is added to the blender and the material is mixed for 3 minutes to obtain the final active blend . tablets can be compressed using a multi layer tablet press such as korsch trp 900 multi layer tablet press . the inactive layer separates the chlorthalidone layer and the lisinopril layer . in this example , all three layers are of equal weight , 150 mg each . total tablet weight is 450 mg and the tablet contains 10 mg of chlorthalidone active and 5 mg of lisinopril active , respectively . the co - formulation of lisinopril and chlorthalidone as a pharmaceutically acceptable syrup is also part of the invention . the liquid , orally dosable solution of lisinopril and chlorthalidone comprises , on a weight to weight basis , about 1 to 2 parts lisinopril to every 1 to 4 parts chlorthalidone , in sufficient pharmaceutically acceptable syrup , to provide a pharmaceutically acceptable dose of the lisinopril - chlorthalidone combination . the intention is to allow a patient in need thereof to take a liquid dose of lisinopril and chlorthalidone appropriate for the treatment , in a convenient 5 to 10 ml or so amount with the absolute amount of lisinopril and chlorthalidone being varied so as to give the appropriate dosage of the lisinopril and chlorthalidone to a patient in need thereof . the co - formulated syrup should be shelf stable meaning that the components of the formulation should not settle and the syrup will not lose potency or support bacterial contamination . other stable liquid suspensions of lisinopril and chlorthalidone with the following ratios can be made , where the dosage form is selected from : about 2 to 5 milligrams lisinopril and about 2 to 5 milligrams chlorthalidone in 5 milliliter suspension ; about 2 to 5 milligrams lisinopril and about 5 to 10 milligrams chlorthalidone in 5 milliliter suspension ; about 5 to 10 milligrams lisinopril and about 5 to 10 milligrams chlorthalidone in 5 milliliter suspension ; about 5 to 10 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliters suspension ; about 10 to 15 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 10 to 15 milligrams lisinopril and about 15 to 20 milligrams chlorthalidone in 5 milliliter suspension ; about 10 to 15 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 15 to 20 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 15 to 20 milligrams lisinopril and about 15 to 20 milligrams chlorthalidone in 5 milliliter suspension ; about 15 to 20 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 20 to 25 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 20 to 25 milligrams lisinopril and about 15 to 20 milligrams chlorthalidone in 5 milliliter suspension ; about 20 to 25 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 20 to 25 milligrams lisinopril and about 25 to 30 milligrams chlorthalidone in 5 milliliter suspension ; about 25 to 35 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 25 to 35 milligrams lisinopril and about 15 to 20 milligrams chlorthalidone in 5 milliliter suspension ; about 25 to 35 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 25 to 35 milligrams lisinopril and about 25 to 30 milligrams chlorthalidone in 5 milliliter suspension ; about 25 to 35 milligrams lisinopril and about 30 to 40 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 15 to 20 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 25 to 30 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 30 to 40 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 40 to 50 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 65 to 80 milligrams chlorthalidone in 5 milliliter suspension ; about 35 to 50 milligrams lisinopril and about 80 to 100 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 15 to 20 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 25 to 30 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 30 to 40 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 40 to 50 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 50 to 65 milligrams chlorthalidone in 5 milliliter suspension ; about 50 to 65 milligrams lisinopril and about 65 to 80 milligrams chlorthalidone in 5 milliliter suspension ; and about 50 to 65 milligrams lisinopril and about 80 to 100 milligrams chlorthalidone in 5 milliliter suspension . another liquid dosage form is selected from the group consisting of : about 2 to 5 milligrams lisinopril and about 2 to 5 milligrams chlorthalidone in 5 milliliter suspension ; about 2 to 5 milligrams lisinopril and about 5 to 10 milligrams chlorthalidone in 5 milliliter suspension ; about 5 to 10 milligrams lisinopril and about 10 to 15 milligrams chlorthalidone in 5 milliliter suspension ; about 10 to 15 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 15 to 20 milligrams lisinopril and about 20 to 25 milligrams chlorthalidone in 5 milliliter suspension ; about 20 to 25 milligrams lisinopril and about 25 to 30 milligrams chlorthalidone in 5 milliliter suspension ; about 25 to 35 milligrams lisinopril and about 30 to 40 milligrams chlorthalidone in 5 milliliter suspension ; and about 35 to 50 milligrams lisinopril and about 40 to 50 milligrams chlorthalidone in 5 milliliter suspension . about 20 milligrams lisinopril and about 12 . 5 milligrams chlorthalidone in 5 milliliter suspension ; about 40 milligrams lisinopril and about 15 milligrams chlorthalidone in 5 milliliter suspension ; and about 40 milligrams lisinopril and about 25 milligrams chlorthalidone in 5 milliliter suspension . a 5 ml suspension containing 5 mg lisinopril and 6 . 25 mg chlorthalidone was prepared by the following process : 400 kg sugar was dissolved in 300 liters of purified water and filtered through a 100 mesh filter into a tank . then a citric acid buffer was prepared using 1 kg citric acid and 4 . 5 kg sodium citrate in 20 l purified water and added to the tank . 100 kg glycerin and 4 kg sodium carboxy methylcellulose were stirred together and added to the tank . 1 . 1 kg of lisinopril dihydrate usp was suspended in 20 l purified water and filtered through a 100 mesh filter into the tank . a suspension of 40 l purified water , 10 kg microcrystalline cellulose and 1 . 25 kg chlorthalidone usp was prepared and filtered through a 40 mesh filter into the tank containing all the other ingredients . 6 kg of strawberry flavor was added although any other suitable flavor could be used . if needed , add purified water to make 1000 l final suspension . the final ph should be between 5 and 6 . 5 ; and the final suspension having the appearance of a white colored suspension is ready to be filled into suitable bottles . a 5 ml suspension containing 20 mg lisinopril and 12 . 5 chlorthalidone was prepared by the following process : 400 kg sugar was dissolved in 300 liters of purified water and filtered through a 100 mesh filter into a tank . then a citric acid buffer was prepared using 1 kg citric acid and 4 . 5 kg sodium citrate in 20 l purified water and added to the tank . 100 kg glycerin and 4 kg sodium carboxy methylcellulose were stirred together and added to the tank . 4 . 40 kg of lisinopril dihydrate usp was suspended in 20 l purified water and filtered through a 100 mesh filter into the tank . a suspension of 40 l purified water , 10 kg microcrystalline cellulose and 2 . 50 kg chlorthalidone usp was prepared and filtered through a 40 mesh filter into the tank containing all the other ingredients . 6 kg of strawberry flavor was added although any other suitable flavor could be used . if needed , add purified water to make 1000 l final suspension . the final ph should be between 5 and 6 . 5 and the final suspension having the appearance of a white colored suspension is ready to be filled into suitable bottles . a 5 ml suspension containing 40 mg lisinopril and 15 mg chlorthalidone was prepared by the following process : 400 kg sugar was dissolved in 300 liters of purified water and filtered through a 100 mesh filter into a tank . then a citric acid buffer was prepared using 1 kg citric acid and 4 . 5 kg sodium citrate in 20 l purified water and added to the tank . 100 kg glycerin and 4 kg sodium carboxy methylcellulose were stirred together and added to the tank . 8 . 80 kg of lisinopril dihydrate usp was suspended in 20 l purified water and filtered through a 100 mesh filter into the tank . a suspension of 40 l purified water , 10 kg microcrystalline cellulose and 3 . 00 kg chlorthalidone usp was prepared and filtered through a 40 mesh filter into the tank containing all the other ingredients . 6 kg of strawberry flavor was added although any other suitable flavor could be used . if needed , add purified water to make 1000 l final suspension . the final ph should be between 5 and 6 . 5 and the final suspension having the appearance of a white colored suspension is ready to be filled into suitable bottles . a 5 ml suspension containing 40 mg lisinopril and 25 mg chlorthalidone was prepared by the following process : 400 kg sugar was dissolved in 300 liters of purified water and filtered through a 100 mesh filter into a tank . then a citric acid buffer was prepared using 1 kg citric acid and 4 . 5 kg sodium citrate in 20 l purified water and added to the tank . 100 kg glycerin and 4 kg sodium carboxy methylcellulose were stirred together and added to the tank . 8 . 80 kg of lisinopril dihydrate usp was suspended in 20 l purified water and filtered through a 100 mesh filter into the tank . a suspension of 40 l purified water , 10 kg microcrystalline cellulose and 5 . 00 kg chlorthalidone usp was prepared and filtered through a 40 mesh filter into the tank containing all the other ingredients . 6 kg of strawberry flavor was added although any other suitable flavor could be used . if needed , add purified water to make 1000 l final suspension . the final ph should be between 5 and 6 . 5 and the final suspension having the appearance of a white colored suspension is ready to be filled into suitable bottles . in all cases , the oral syrup had the specified concentration of lisinopril and chlorthalidone as well as a pharmaceutically acceptable ph range . the suspension was also surprisingly shelf stable as well . dose proportional — where the weight proportionality is maintained so that the granules are exactly the same but the compression weights are proportioned in terms of the active concentration required per tablet . dose similar — where the excipients are the same but the concentrations are not in weight proportioned basis but are based on the need of the individual tablet size and weight desired . however , the ratios of excipients remain the same and hence it is dose similar but not necessarily dose proportional . 0 . 550 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 2 . 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 0 . 625 kg of chlorthalidone was sifted through a 40 mesh screen and 1 . 920 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 2 . 825 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 080 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with an 80 mg tablet weight , each containing 5 mg lisinopril and 6 . 25 mg chlorthalidone . 1 . 100 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 4 , 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 0 . 625 kg of chlorthalidone was sifted through a 40 mesh screen and 3 . 840 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 5 . 650 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 160 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 153 . 75 mg tablet weight , each containing 10 mg lisinopril and 6 . 25 mg chlorthalidone . 3 . 300 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 12 . 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 1 . 250 kg of chlorthalidone was sifted through a 40 mesh screen and 11 . 520 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 16 . 950 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 480 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 455 . 00 mg tablet weight , each containing 30 mg lisinopril and 12 . 5 mg chlorthalidone . 4 . 400 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 16 . 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 1 . 500 kg of chlorthalidone was sifted through a 40 mesh screen and 15 . 360 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 22 . 600 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 640 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 605 . 00 mg tablet weight , each containing 40 mg lisinopril and 15 mg chlorthalidone . 4 . 400 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 16 . 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 2 . 500 kg of chlorthalidone was sifted through a 40 mesh screen and 15 . 360 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 22 . 600 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 640 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 615 . 00 mg tablet weight , each containing 40 mg lisinopril and 25 mg chlorthalidone . 0 . 550 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 2 . 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 0 . 625 kg of chlorthalidone was sifted through a 40 mesh screen and 1 . 920 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 2 . 825 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 080 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with an 80 mg tablet weight , each containing 5 mg lisinopril and 6 . 25 mg chlorthalidone . 1 . 100 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 4 , 000 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 0 . 625 kg of chlorthalidone was sifted through a 40 mesh screen and 4 . 465 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 5 . 650 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 160 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 160 . 00 mg tablet weight , each containing 10 mg lisinopril and 6 . 25 mg chlorthalidone . 3 . 300 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 5 . 992 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 1 . 250 kg of chlorthalidone was sifted through a 40 mesh screen and 5 . 753 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 8 . 465 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 240 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 250 . 00 mg tablet weight , each containing 30 mg lisinopril and 12 . 5 mg chlorthalidone . 4 . 400 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 8 . 528 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 1 . 500 kg of chlorthalidone was sifted through a 40 mesh screen and 8 . 186 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 12 . 045 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 341 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 350 . 00 mg tablet weight , each containing 40 mg lisinopril and 15 mg chlorthalidone . 4 . 400 kg of lisinopril dihydrate usp was sifted through a 40 mesh screen , 8 . 234 kg of d - mannitol was sifted through a 20 mesh screen and the lisinopril and mannitol were then blended together in a double cone blender . 2 . 500 kg of chlorthalidone was sifted through a 40 mesh screen and 7 . 905 kg of dicalcium phosphate was sifted through a 20 mesh screen . the chlorthalidone and dicalcium phosphate were then blended together in a double cone blender . the lisinopril - mannitol mixture was then added to the chlorthalidone - dicalcium phosphate mixture . 11 . 631 kg of sodium starch glycollate was sifted through a 100 mesh screen and then added to the lisinopril - chlorthalidone mixture and the resulting mixture was then blended together . 0 . 330 kg of magnesium stearate was sifted through an 80 mesh screen and then added to the blended lisinopril - chlorthalidone mixture . after blending , the mixture was compressed in a double rotary compression machine to make 100 , 000 tablets with a 350 . 00 mg tablet weight , each containing 40 mg lisinopril and 25 mg chlorthalidone . both the dose proportional and the dose similar had suitable pharmaceutical properties in terms of disintegration times , tablet hardness and correct proportion of lisinopril to chlorthalidone throughout the tablet run .
the invention describes fixed dosage formulations of an angiotensin converting enzyme inhibitor , preferably lisinopril and the diuretic , preferably chlorthalidone in the same pharmaceutically acceptable carrier , for example a tablet , capsule or oral suspension and methods of treating hypertension by administering the fixed dosage formulation of lisinopril and chlorthalidone to a patient in need thereof .